We therefore analysed gene expression profiles from pharmacotherapy-sensitive and -resistant breast cancer cell lines12 and found that high GR expression was correlated with resistance to the mammalian target of rapamycin inhibitor AZD8055, AKT inhibitor MK2206 and mitotic kinesin Eg5 inhibitor S-trityl-L-cysteine (Fig. 1a). The gene discussed is NR3C1; the disease is breast carcinoma.